1. Home
  2. MCB vs CGEM Comparison

MCB vs CGEM Comparison

Compare MCB & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$89.80

Market Cap

957.3M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.36

Market Cap

873.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCB
CGEM
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
957.3M
873.4M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
MCB
CGEM
Price
$89.80
$14.36
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$97.50
$30.11
AVG Volume (30 Days)
113.7K
720.0K
Earning Date
04-21-2026
05-07-2026
Dividend Yield
0.89%
N/A
EPS Growth
11.64
N/A
EPS
6.62
N/A
Revenue
$11,053,000.00
N/A
Revenue This Year
$37.22
N/A
Revenue Next Year
$14.75
$5.20
P/E Ratio
$13.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.83
$5.68
52 Week High
$97.84
$16.74

Technical Indicators

Market Signals
Indicator
MCB
CGEM
Relative Strength Index (RSI) 68.89 52.98
Support Level $72.51 $11.43
Resistance Level $97.29 $16.74
Average True Range (ATR) 2.09 0.91
MACD 1.14 0.04
Stochastic Oscillator 94.34 59.74

Price Performance

Historical Comparison
MCB
CGEM

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: